Stacks a long-acting amylin agonist onto tirzepatide's dual GIP/GLP-1 action, aiming to push fat-loss and metabolic-marker improvement beyond either compound alone, and in principle allowing lower per-drug doses for the same or better effect.
Why it matters
Tirzepatide is an approved drug that curbs appetite through two gut-hormone pathways; cagrilintide would add a third, separate one (amylin, a satiety hormone).
The published per-compound doses, timing, cycle length, the mechanism sources give for why it's combined, and the harm-reduction notes — the parts that took the most research to get right — are part of membership.
